Fig. 1.

HIPEC-induced acute kidney injury in patients. a Occurrence of AKI after HIPEC regimens containing (CPL+) and not containing (CPL−) cisplatin. CPL cisplatin, DOX doxorubicin, LV leucovorin, MMC mitomycin C, OXA oxaliplatin, TAX taxol, 5-FU 5-fluorouracil. b Staging of patients (n = 45) with HIPEC-induced kidney injuries according to KDIGO classification. c Comparison of urine output and d fluid balance between patients with (AKI+) and without (AKI−) kidney injury after HIPEC on day of operation (0th), 1st, and 2nd POD. Data are expressed as mean ± range. e Quantity of patients diagnosed with HIPEC-induced AKI per postoperative day. *p < 0.05; ^nsp ≥ 0.05